Sentences with phrase «on cancer therapy»

The researchers now want to apply this information on cancer therapy in humans.

Of 12 major, large - cap biopharmaceutical companies examined by Deloitte, the industry appears to be homing in on cancer therapies — and for a good economic reason.

«The US spends $ 90bn on cancer therapies annually and about 75 % of that fails to provide the intended clinical benefit of prolonged patient survival.»

At the time, she was newly married and living in California, working on cancer therapies for a small drug - development firm.

Most people live with the infection without noticeable effect, but it can be life - threatening for people with suppressed immune systems, such as people on cancer therapies or who have HIV / AIDS.

Not exact matches

«In the long term, we want to be able to send energy to and communicate with implants all over the body, to record data from a variety of organs in many different ways, maybe even report on the conditions of tumors or cancer therapies,» Maharbiz says.

The Food and Drug Administration (FDA) on Tuesday gave Swiss drug giant Novartis a second approval for its pioneering CAR - T cancer therapy, which uses patients» own immune cells (re-engineered outside the body and then replicated) to destroy blood cancers.

The falling rate of cancer - related deaths is clearly an impressive achievement, and may be partially attributable to drug makers» increased focus on developing novel new therapies to fight cancers.

Basically, CAR - T therapy involves taking a patient's own immune «killer» T - cells, inserting new genetic code into those cells which turn them into cancer - hunters that can home in on malignant B - cells (another kind of immune cell), and then pumping these specialized leukemia - busting cells back into the patient.

The treatment is a type of so - called CAR T - cell therapy — taking a patient's own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient.

«There's already fantastic therapies to overcome heart disease, cancer and every other neurological disease based on this idea of reprogramming the software,» Kurzweil said.

On Wednesday, the U.S. Food and Drug Administration approved Novartis» Kymriah, the first drug for a new kind of cancer treatment called CAR - T cell therapy.

His research has spanned hematopoiesis, gene therapy, stem cell biology, genomics and cancer, consistently focusing on bringing the very latest research advances to patients with heretofore incurable diseases.

After all, «biotech» is a pretty broad category that encompasses everything from next - gen cancer therapy makers that are already on the market and racking up sales to firms that are still years away from even filing for their first FDA approval.

PERTH - based Medi - tech Research Limited may be on the brink of a major advance in cancer therapy with its hyaluronic acid technology for the delivery of anti-cancer drugs.

The race to become the first company with a chimeric antigen receptor T - cell (CAR - T) cancer therapy on the market has entered its final leg, and Kite Pharma now appears to have a big advantage.

The Kamens claim the main thing that distinguishes their foundation from other brain tumor foundations is their focus on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.

BioNTech, which has around 700 employees at sites in Germany — more than any other unlisted biotech firm in Europe — is also working on other cancer - fighting technologies, including antibodies, cell therapies and small molecules.

But he adds that the industry has entered a new cycle where targeted therapies, particularly in cancer treatments, means there are some good returns on R&D.

Publishing a commentary about Bitcoin by an institutional economics professor is as responsible as letting a village witch doctor give lectures on the merits of proton radiation therapy to treat cancer («The Bitcoin myth,» March 3).

Overcoming the immense logistical challenges involved with withdrawing, shipping, modifying, returning, then reinfusing cells for every patient treated paints a scary question mark on the future of cell - based cancer therapies.

There was also no change based on whether patients had undergone hormone therapy, a common treatment for prostate cancer which lowers the male hormone and can be combined with daily radiation.

During this in depth study, an international team of researchers led by British scientists investigated the impact of anti-hormone therapy on samples taken from patients with prostate cancer.

In the spring, the U.S. Food and Drug Administration approved an antibody that is the first cancer therapy based on a tumor genetic biomarker instead of a location in the body.

Currently, most cancer therapy relies on frontal assaults on malignant cells.

A transformative cancer therapy based on modified immune cells has lured doctors, companies, and patients alike, but many are hitting a frustrating roadblock: generating enough of these chimeric antigen receptor (CAR)- T cells to meet surging demand.

On its own, this immune response had no immediate effect in the fight against the utilized breast tumors, but in combination with the ADC it proved itself effective in attacking cancer cells in mice, resulting in the complete cure of the majority of mice receiving the combination therapy.

While the combination therapies block off the principal pathway that cancer cells use to fuel their growth, the cells come to bypass this blockade and, like vehicles on a detour route, make use of additional pathways to continue growing and spreading.

Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cCancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancercancer.

«Cervical cancer patients are currently treated as a uniform group based on chemotherapy and radiation regimens that help the largest percentage of people; however, one third of these patients are not helped by standard therapies,» Banister said.

«Current therapies in clinical trials are focused on targeting genetic changes in tumors and helping to boost one's immune system to fight the cancer cells.

The scientists also tested the therapy on tumors taken from two patients who had not responded to conventional therapy for their glioblastoma, a deadly form of brain cancer.

Because the impact of autophagy on cancer seems to go both ways, cancer trials have tested therapies that enhance autophagy as well as drugs that block it.

But success could leave a lasting mark on cancer care, by helping hundreds of thousands of patients every year, far more than other genetically targeted therapies.

Patients with metastatic non-small cell lung cancer will always progress after chemotherapy, so most patients go on to be treated with immunotherapy, a type of therapy that uses the body's immune system to fight cancer.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

«If cancer recurs, it may be because the therapy didn't hit key mature cells that take on stem cell - like behavior.

Treatments aimed at revving up the immune system's attack on the cancer may be the most promising approach to cancer therapy since combination chemotherapy.

The U.S. attorney's office in Indianapolis had alleged that Guoqing Cao and Shuyu Li, both naturalized U.S. citizens and senior biologists at Eli Lilly, passed research on tailored therapies for cancer and drugs to treat diabetes, obesity, and other metabolic disorders to Jiangsu Hengrui Medicine, a company in Lianyungang, China.

EMD Serono, Kirschbaum says, «focuses on the development of targeted cancer therapies on three therapeutic platforms: targeting the tumor cell, the tumor environment, and the immune system.»

Development of new therapies for the prevention and treatment of prostate cancer bone metastasis depends on understanding the dynamic reciprocal interactions between prostate cancer cells and the bone microenvironment.

These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.

«It was kind of fun being at a medical school and known as the weird guy who worked with dogs,» says Modiano, who is now a professor of comparative oncology at the University of Minnesota College of Veterinary Medicine and the Masonic Cancer Center, where his research focuses on immunology, cancer cell biology, cancer genetics, and applications of gene thCancer Center, where his research focuses on immunology, cancer cell biology, cancer genetics, and applications of gene thcancer cell biology, cancer genetics, and applications of gene thcancer genetics, and applications of gene therapy.

Finding a cure or a better therapy for cancer will relieve the burden on the patient's family, on the health system and society as well.

This method will facilitate the analysis of patient tumors and the selection of the most appropriate therapy based on the individualized features of each patient's cancer subtype.

«However, patients eventually experience progression of cancer on this treatment, highlighting the need for additional therapies.

To the Penn scientists, the findings indicate that blocking the CCL2 - CCR2 inflammatory pathway in pancreatic cancer is worth investigating as an add - on to radiation therapy, not just to chemotherapy.

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.

Before moving on to human trials, they will need to study all instances of «off - target» effects: Years before Crispr, the viruses employed to deliver DNA in gene therapy trials occasionally damaged the whole system, causing cancer.

These results not only show promise on a new targeted therapy to treat this malignancy, as PI3K inhibitors are already used in the clinical practice, but also unravel a new function of the PI3K kinase in cancer biology through its role in promoting metastasis.